1例帕金森病相关恶性综合征患者的药学监护  

Pharmaceutical Care of a Case of Patient with Parkinson’s Disease-related Malignant Syndrome

作　　者：单荟芳 刘静[1] 魏春燕[1] 徐珽[1] Shan Huifang;Liu Jing;Wei Chunyan;Xu Ting(Department of Clinical Pharmacy,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院临床药学部,成都610041

出　　处：《药物流行病学杂志》2021年第10期701-705,共5页Chinese Journal of Pharmacoepidemiology

摘　　要：本文报道了临床药师通过参与1例疑似抗帕金森病药物撤药致恶性综合征患者的诊疗过程,结合患者的临床表现及检验指标,分析其意识障碍原因及发病机制,为抗帕金森病恶性综合征患者的临床鉴别提供经验参考。同时,通过查阅文献资料,参与药品不良反应治疗方案的讨论与制定,对癫痫的预防、经验性抗感染、是否启动抗凝治疗等多方面提供个体化用药建议,并进行药学监护。在药物治疗的过程中,临床药师不仅需要协助医生制定个体化治疗方案,还需具备甄别药品不良反应的能力,及时干预,降低药物风险。This paper reported that a clinical pharmacist participated in the diagnosis and treatment of a patient with suspected malignant syndrome caused by withdrawal of anti-Parkinson’s disease drugs. According to the patient’s clinical feature and assay index, clinical pharmacist analyzed the cause and pathogenesis of the disorder of consciousness. Finally, experience reference for the clinical identification and drug treatment of the malignant syndrome was provided. At the same time, through consulting the literature and participating in the discussion and formulation of the adverse drug reaction treatment plan, clinical pharmacist provided individualized medication recommendations for epilepsy prevention, empirical anti-infection, whether to start anticoagulation and other aspects and performed pharmaceutical monitoring. In summary, In drug treatment, clinical pharmacists not only need to assist doctors in formulating individualized treatment plans, but also have the ability to identify adverse drug reactions, intervene in time, and reduce drug risks.

关 键 词：恶性综合征 抗帕金森病药物 药品不良反应 药学监护 

分 类 号：R97[医药卫生—药品]